[Several new inhibitors of gastric secretion].
In experiments on dogs, milid (proglymid) entailed a weak inhibition of the 2nd phase of the gastric secretion leaving intact the 1st phase. The action of LS-519 was obvious in the 1st phase, having entailed a significant inhibition. The glycomacropeptid exerted a strong inhibiting effect both on the 1st and the 2nd phases, the effect lasting longer than that of the first two drugs. All the three drugs not only inhibited the gastric secretion but increased pH, reduced the gastric juice acidity while exerting no significan effect on concentration of common proteinases.
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D003864:Depression, Chemical; D004285:Dogs; D005750:Gastric Juice / Q000032:analysis / Q000201:enzymology / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects*; D005973:Glutamine / Q000031:analogs & derivatives*; D006020:Glycopeptides / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006863:Hydrogen-Ion Concentration; D010447:Peptide Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011377:Proglumide / Q000494:pharmacology*
D001570:Benzodiazepinones; D006020:Glycopeptides; D006635:Histamine H2 Antagonists; D010879:Piperazines; D005973:Glutamine; D010447:Peptide Hydrolases; D011377:Proglumide
Issledovanie nekotorykh novykh ingibitorov zheludochnoĭ sekretsii.